definiens: within the meaning of the Private Securities Litigation Reform Actof 1995 . These forward - looking statements are based on the current intent and expectations of the management ofZymoGenetics . These statements are not guarantees of future performance and involve risks and uncertainties that aredifficult to predict . [COMPANY] actual results and the timing and outcome of events may differ materially from thoseexpressed in or implied by the forward - looking statements because of risks associated with [COMPANY] dependence onNovo Nordisk to develop and commercialize IL-21 mAb . In particular, [COMPANY] ability to generate revenues from thelicense arrangement is subject to numerous risks, including, among other things : the possibility that Novo Nordisk chooses toscale back or discontinue its development of IL-21 mAb due to, among other things, changes in its strategies, restructuring, mergers or acquisitions ; the Schedule 2 - 2- ® possibility that clinical trials involving IL-21 mAb reveal that it is not effective or has undesirable side effects, unacceptabletoxicities or other characteristics that preclude regulatory approval or prevent or limit commercial use ; and the length oftime that it takes for Novo Nordisk to solve technical problems or achieve various clinical development and regulatoryapproval milestones . In addition, the forward - looking statements in this press release are subject to the other risks detailedin the other risks detailed in the [COMPANY] Annual Report on Form 10 - K for the year ended December 31, 2008,Quarterly Report on Form 10 - Q for the quarter ended June 30, 2009 and from time to time in other reports filed byZymoGenetics with the U.S. Securities and Exchange Commission . Except as required by law, [COMPANY] undertakes noobligation to update any forward - looking or other statements in this press release, whether as a result of new information, future events or otherwise